University of Kentucky

UKnowledge
Sanders-Brown Center on Aging Faculty
Publications

Aging

8-22-2017

Investigation of the Safety of Focused Ultrasound-Induced BloodBrain Barrier Opening in a Natural Canine Model of Aging
Meaghan Anne O'Reilly
Sunnybrook Research Institute, Canada

Ryan Matthew Jones
Sunnybrook Research Institute, Canada

Edward Barrett
Lovelace Respiratory Research Institute

Anthony P. Schwab
University of Kentucky, anthony.schwab@uky.edu

Elizabeth Head
University of Kentucky, elizabeth.head@uky.edu
Follow this and additional works at: https://uknowledge.uky.edu/sbcoa_facpub
See next page for additional authors
Part of the Disease Modeling Commons, Investigative Techniques Commons, Neuroscience and
Neurobiology Commons, and the Therapeutics Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
O'Reilly, Meaghan Anne; Jones, Ryan Matthew; Barrett, Edward; Schwab, Anthony P.; Head, Elizabeth; and
Hynynen, Kullervo, "Investigation of the Safety of Focused Ultrasound-Induced Blood-Brain Barrier
Opening in a Natural Canine Model of Aging" (2017). Sanders-Brown Center on Aging Faculty
Publications. 90.
https://uknowledge.uky.edu/sbcoa_facpub/90

This Article is brought to you for free and open access by the Aging at UKnowledge. It has been accepted for
inclusion in Sanders-Brown Center on Aging Faculty Publications by an authorized administrator of UKnowledge.
For more information, please contact UKnowledge@lsv.uky.edu.

Investigation of the Safety of Focused Ultrasound-Induced Blood-Brain Barrier
Opening in a Natural Canine Model of Aging
Digital Object Identifier (DOI)
https://doi.org/10.7150/thno.20621

Notes/Citation Information
Published in Theranostics, v. 7, issue 14, p. 3573-3584.
© Ivyspring International Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BYNC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full
terms and conditions.

Authors
Meaghan Anne O'Reilly, Ryan Matthew Jones, Edward Barrett, Anthony P. Schwab, Elizabeth Head, and
Kullervo Hynynen

This article is available at UKnowledge: https://uknowledge.uky.edu/sbcoa_facpub/90

Theranostics 2017, Vol. 7, Issue 14

3573

Ivyspring
International Publisher

Research Paper

Theranostics

2017; 7(14): 3573-3584. doi: 10.7150/thno.20621

Investigation of the Safety of Focused UltrasoundInduced Blood-Brain Barrier Opening in a Natural
Canine Model of Aging
Meaghan Anne O’Reilly1,2, Ryan Matthew Jones1,2, Edward Barrett3, Anthony Schwab4, Elizabeth Head4
and Kullervo Hynynen1,2,5
1.
2.
3.
4.
5.

Physical Sciences Platform, Sunnybrook Research Institute, Toronto, Ontario, Canada
Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
Lovelace Respiratory Research Institute, Albuquerque, New Mexico, USA
Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA
Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada

 Corresponding author: Meaghan A. O’Reilly Sunnybrook Research Institute, 2075 Bayview Avenue, C736a, Toronto, Ontario, M4N 3M5, Canada;
moreilly@sri.utoronto.ca; +1 416 480 5043
© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license
(https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2017.04.17; Accepted: 2017.06.06; Published: 2017.08.22

Abstract
Rationale: Ultrasound-mediated opening of the Blood-Brain Barrier(BBB) has shown exciting
potential for the treatment of Alzheimer’s disease(AD). Studies in transgenic mouse models have
shown that this approach can reduce plaque pathology and improve spatial memory. Before clinical
translation can occur the safety of the method needs to be tested in a larger brain that allows
lower frequencies be used to treat larger tissue volumes, simulating clinical situations. Here we
investigate the safety of opening the BBB in half of the brain in a large aged animal model with
naturally occurring amyloid deposits.
Methods: Aged dogs naturally accumulate plaques and show associated cognitive declines.
Low-frequency ultrasound was used to open the BBB unilaterally in aged beagles (9-11yrs, n=10) in
accordance with institutionally approved protocols. Animals received either a single treatment or
four weekly treatments. Magnetic resonance imaging(MRI) was used to guide the treatments and
assess the tissue effects. The animals underwent neurological testing during treatment follow-up,
and a follow-up MRI exam 1 week following the final treatment.
Results: The permeability of the BBB was successfully increased in all animals (mean
enhancement: 19±11% relative to untreated hemisphere). There was a single adverse event in the
chronic treatment group that resolved within 24 hrs. Follow-up MRI showed the BBB to be intact
with no evidence of tissue damage in all animals. Histological analysis showed comparable levels of
microhemorrhage between the treated and control hemispheres in the prefrontal cortex
(single/repeat treatment: 1.0±1.4 vs 0.4±0.5/5.2±1.8 vs. 4.0±2.0). No significant differences were
observed in beta-amyloid load (single/repeat: p=0.31/p=0.98) although 3/5 animals in each group
showed lower Aβ loads in the treated hemisphere.
Conclusion: Whole-hemisphere opening of the BBB was well tolerated in the aged large animal
brain. The treatment volumes and frequencies used are clinically relevant and indicate safety for
clinical translation. Further study is warranted to determine if FUS has positive effects on naturally
occurring amyloid pathology.
Key words: Blood-Brain Barrier, Focused Ultrasound, Alzheimer’s Disease
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Introduction
Ultrasound-mediated
opening
of
the
Blood-Brain Barrier (BBB) is an area of increasing
research due to its potential to significantly impact the
treatment of brain disorders. The BBB regulates the
passage of molecules from the vasculature to the brain
parenchyma to maintain the brain environment, and
in doing so prevents most intravenouslyadministered therapeutic agents from reaching the
brain tissue in therapeutically relevant quantities [1].
One method to circumvent the BBB is to transiently
open it using ultrasound [2]. When ultrasound
interacts with intravenous diagnostic ultrasound
contrast agents, micron-sized gas spheres known as
‘microbubbles’, it causes them to oscillate in the
vasculature. The microbubbles stimulate the blood
vessels in the brain and cause a transient opening
lasting a few hours in length where therapeutics
ranging
in
size
from
small
molecule
chemotherapeutics [3, 4, 5], to antibodies [6, 7],
gene-delivery vectors [8, 9, 10] and stem cells [11] can
be delivered. Investigations in non-human primates
have demonstrated a good safety profile for this
technique [12, 13, 14], and initial clinical
investigations in brain tumor patients are underway
in France [15] and Canada [16].
These methods also show promise in the
treatment of Alzheimer’s disease (AD). The first
studies in mouse models of AD found that using
ultrasound to deliver an anti-Amyloid β antibody
resulted in a reduction of beta-amyloid (Aβ) plaque
pathology 4 days post-treatment [6]. Interestingly, a
later study showed that ultrasound opening of the
BBB, in the absence of an externally administered
therapeutic, also produced a positive effect on plaque
load, presumably due to the treatment facilitating
endogenous antibodies to reach the brain and/or
activation of microglial cells [17]. Further, repeated
opening of the BBB with ultrasound alone improves
memory in two different transgenic mouse models of
AD [18, 19].
Unlike mouse models of AD, which rely on
genetic modification and overexpression [20], aged
dogs naturally develop pathology and cognitive
deficits [21]. Although the safety of this approach has
been tested in large animals in the healthy brain [12,
13] safety in the aged, pathologic brain remains to be
confirmed. It is unclear from the current literature if
the aged brain will be as robust against the
mechanical insult from the ultrasound and
microbubbles. In addition, the larger brain of beagles
allows clinically relevant low frequencies that
penetrate the skull to be used in a larger skull cavity
without significant impact from standing waves, as is
case in the small skull of rodents [22]. Similarly, the
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tissue volume exposed in the dog brain can simulate
the volumes needed to be exposed in clinical
treatments. Therefore, this natural model allows
investigations of BBB opening for the treatment of AD
as a precursor to clinical investigations. In this study
we investigate the safety of single and repeated BBB
opening treatments in aged beagles (9-11yrs), which is
an age at which most animals will have Aβ
deposition. The results of these treatments and a two
week follow-up period are reported.

Materials and Methods
Study Design
The objective of this study was to test the safety
of ultrasound-mediated BBB opening in the aged
brain with clinically relevant exposure conditions and
treatment volumes. Aged beagle dogs (n=10, 9-11yrs,
10.1-13.8kg) with naturally occurring amyloid
pathology were used, in accordance with
institutionally approved protocols (Sunnybrook
Research Institute animal care committee) and in
keeping with the Canadian Council on Animal Care
guidelines on the care and use of laboratory animals.
The animals were divided into two groups (each n=5),
the first receiving a single treatment, and the second
group receiving weekly treatments for four weeks.
The effects were monitored using MRI, neurological
testing and histological analysis.

Animal Preparation
The animals had a range of underlying medical
conditions, including cancer, and this was an
end-of-life study prior to euthanasia. Anesthesia was
induced
with
acepromazine
(0.2mg/kg,
intramuscular). The animals were intubated and
anesthesia was maintained using oxygen and 2%
isofluorane. The carrier gas was changed to medical
air 10 mins prior to the first treatment sonication. The
cephalic or saphenous vein was catheterized using a
22-20G angiocatheter. The hair on the head was
removed using an electric razor and depilatory cream.
The animals were mechanically ventilated
during the treatment and imaging procedures, and
the heart rate was monitored using a pulse oximeter.
While anesthetized, the body temperature was
maintained using a circulating water blanket and was
regularly checked using a rectal thermometer.
The animals were assigned to one of two groups.
In the first group the animals received a single
ultrasound treatment and then were followed for two
weeks. After no significant adverse effects were
observed following the single treatment, a second
group of animals received treatments weekly for 4
weeks, followed by a 2 week follow-up period.
http://www.thno.org
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Ultrasound Exposures
For the treatments, the animals were positioned
supine above an MRI-compatible three-axis
positioning system, operationally similar to that
described by Ellens et al [23], that would mechanically
position the ultrasound focus by moving a
single-element, fixed focus transducer. The
experimental setup is illustrated in Fig.1. The
ultrasound was generated by an in-house assembled,
spherically curved, lead zirconate titanate (PZT)
transducer (PZT from DeL Piezo Specialties, LLC,
West Palm Beach, Florida), with a 75 mm diameter,
focal-number 0.8 and fundamental frequency, f0 = 0.28
MHz. The transducer was matched to 50 Ω, 0° at its
fundamental frequency using an external matching
circuit, and driven using a function generator
(33220A; Agilent, Santa Clara, California) and an RF
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amplifier (NP2519; NP Technology, Newbury Park,
California). Sonications were applied transcranially.
All pressure estimates reported in this paper are
based on the calibration of the transducer in water
using a fiber-optic hydrophone (Precision Acoustics,
Ltd, UK) and are not de-rated for transmission
through the skull-bone due to the wide variation in
cranial geometry, and hence insertion loss, between
animals (Fig.2). The measured dimensions of the
transducer focal spot (full-width-at-half-maximum
pressure) were 6.5 mm in the transverse direction, and
40 mm axially. The insertion loss at 280 kHz was
measured in 4 of the skull caps following tissue
harvest using the fiber-optic hydrophone system.
Measurements of the focal pressure amplitude were
made at a total of 20 locations across the 4 skulls and a
mean (± S.D.) transmission of 53 ± 15% was measured.

Fig.1. A) Experimental setup. A coronal T2-weighted MR image shows the orientation of the transducer with respect to the subject. B) Example sonication grids
overlaid on an axial T2-weighted MR image. Solid white circles: 2x2 grid with 4.5 mm spacing, Dashed white circles: 1x4 line with 4.5 mm spacing, Solid black circles:
reduced, 3 point grid with 4.5 mm spacing to fit the brain geometry at the edges of the brain cavity. The dashed black line indicates the brain midline. The diameter
of the circles is the approximate FWHM of the focal spot. C) Example pressure vs. time curve for one sonication focus, showing the peak negative pressure (free-field)
for each burst of ultrasound. The black and red circles correspond to timepoints below (black) and at (red) the threshold for detecting ultraharmonic microbubble
behavior. The spectra corresponding to these two bursts are overlaid in (D), where signals at 0.42 and 0.7 MHz (1.5f0 and 2.5f0) are seen in the red trace.

http://www.thno.org
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Fig.2. CT skull cross-sections (coronal) from (top) the 5 subjects in the acute treatment group, and (bottom) the 5 subjects in the repeat treatment group. The sex,
age and weight of the subjects at the time of treatment are shown. The scale bar is 2 cm.

Definity microbubbles (Lantheus Medical
Imaging, N. Billerica, MA, USA) were used to
potentiate the BBB opening effect and were injected
simultaneously with the start of the ultrasound
exposure at a dose of 0.02 ml/kg per injection. The
mechanical positioning system used is limited in the
speed of travel between treatment points. For the 10
ms ultrasound bursts used in this study, the
positioner could rapidly move to and treat up to 4
points at 4.5 mm spacing within 1 second, allowing
for a 1 Hz pulse repetition frequency (PRF) per point.
A larger number of focal points could be treated in
one sonication (one bubble injection) by reducing the
PRF to allow more time to cycle through the targets.
In the first animal the sonications were 3 minutes in
length, and consisted of 10 ms bursts at a 0.33 Hz, per
point PRF, for a total of 60 bursts per target. The 0.33
Hz PRF allowed 3 seconds for the positioning system
to cycle through 9 targets in a 3x3 grid with 4 mm
spacing. The sonication pressure was fixed for the
sonication and ranged from 0.8-1 MPa (free-field
estimate). In the remaining 9 animals the treatment
pressures were modulated during the sonications,
using the control scheme reported in [24], which is
also briefly described in the following: Microbubble
emissions during the sonications were captured to PC
with a sampling rate of 20 MHz and an 11 ms capture
length using a wideband, PVDF receiver [25]
connected to a 14 Bit PCI digitizer (ATS460, Alazar
Tech, Pointe Claire, Quebec). After each burst the
frequency content of the data was analyzed. Starting
at a value of 0.6-1 MPa, the pressure was increased by
0.016 MPa for each subsequent burst until
ultraharmonic microbubble emissions (1.5f0 or 2.5f0)
were detected. Prior work in rats has shown that these
emissions precede the appearance of wideband

emissions indicating inertial cavitation, and can thus
be used as an internal calibration point to stay below
the threshold for tissue damage [24]. This means that
each sonication point received an acoustic exposure
based on the acoustic emissions detected, thus
minimizing the variations caused by skull thickness
and angle of incidence [26, 27, 28]. The peak pressure
(mean ± S.D.) reached in these sonications was 1.2 ±
0.3 MPa. Following detection of the ultraharmonic
signals the pressure was decreased by 50 % and
maintained for the remainder of the sonication
(Fig.1C, D). The actively controlled sonications were
performed at a 1Hz PRF for a total of 2 minutes (120
bursts per target) using 2 x 2 or 1 x 4 interleaved target
grids with 4.5 mm spacing (Fig.1B). At the edges of
the brain, some sonications were reduced to 3 or 2
points to fill the remaining space without overlapping
previous sonications. For both sonication schemes the
sonications were repeated with new targets until the
entire hemisphere had been treated. A minimum of 5
minutes was allowed between sonications for the
microbubbles from the previous injection to clear. The
total number of sonications with separate
microbubble injections varied between 7 and 13 per
treatment with a mean value of 9 ± 2. The total
number of foci sonicated in this study was 920. This
value is the total number of focal spots required to
cover the treated hemisphere, summed over all
animals and all treatments.

CT and MRI Imaging
All animals were imaged in an x-ray computed
tomography (CT) scanner (Aquilon ONE, Toshiba
America Medical Systems, Inc., Tustin, California).
The field of view was adjusted slightly based on the
animal size and was reconstructed using a 512x 512
http://www.thno.org
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image matrix, resulting in voxel dimensions that
varied slightly between animals but were at most 0.35
x 0.35 x 1 mm3. The CT images were captured to allow
better visualization of the skull geometry and porosity
to anticipate potential issues with sound transmission
during the treatments.
The MRI parameters used are summarized in
Table 1. All treatments were performed under
MRI-guidance at 3T (Signa MR750, GE Healthcare,
Milwaukee, Wisconsin). Baseline T1 and T2 weighted
images were obtained and are shown for group 1 in
Fig.3. Contrast-enhanced (CE) T1 weighted imaging
(0.1 ml/kg Gadovist) was used to assess the integrity
of the BBB post-treatment, and post-treatment T2 and
T2* images were used to identify edema or
hemorrhage. Follow-up MR imaging was performed
one week following the final treatment, using CE-T1,
T2 and T2* weighted imaging. The follow-up imaging
was performed on the same MRI scanner used during
the treatments, except in one case where the system
was unavailable and an alternate 3T platform was
used (MAGNETOM Prisma, Siemens Healthcare,
Erlangen, Germany).
Table 1. MRI parameters
GE
T1
T2
Fast spin Fast
echo
spin
echo
Echo time (ms)
14.52
58.08
Repetition time (ms) 500
3000
Echo train length
4
4
Averages
3
1
Field of view (cm)
14x14
14x14
Matrix
256x256 256x256
Slice thickness (mm) 1.5
1.5
Parameter
Sequence type

T2*
3D
gradient
echo
3.3348
8.108
1
1
14x14
256x256
1

Siemens
T1
T2
Turbo Turbo
spin
spin
echo
echo
16
79
500
3000
4
8
2
2
14x14 14x14
128x128 128x128
1.5
1.5

T2*
3D
gradient
echo
15
27
1
2
14x14
128x128
1

Neurological Testing
The animals were subjected to a neurological
exam 24 hrs after the ultrasound treatment (Group 1)
or daily beginning 72 hrs before the first treatment
and continuing until the study end (Group 2). The
exam included observations of general mental status,
posture and movement, as well as cranial nerve
function and postural reactions. The complete
neurological exam criteria are included in Table 2. The
testing did not assign a numeric score as the criteria
were assessed as pass/fail, with animals either having
a consistent response with their prior health history or
baseline data, or an abnormal response.

Histological Processing and Analysis
Two weeks following the final treatment in each
group, the animals were deeply anesthetized and

sacrificed using approved animal protocols. Brains
were fixed in 4% paraformaldehyde for 48-72 hrs
prior to transfer to phosphate buffered saline (pH 7.4)
and storage at 4⁰C. The prefrontal cortex was
dissected from both the left and right side for all
animals and sectioned at 50µm using a vibratome.
This is typically the brain region affected earliest by
Aβ deposition in beagles [29]. Tissue was stained for
Aβ
plaques
using
previously
published
immunohistochemical methods [30] with 6E10
antibody (Aβ1-16, Covance, Dedham, MA; 1:3000,
mouse monoclonal) after the tissue was pre-treated in
90% formic acid for 4 min [31]. Adjacent sections were
used for microglial immunostaining with the IBA-1
antibody (for possible inflammation, Wako Chemicals
USA, Richmond, VA, 1:800, rabbit polyclonal) and
Prussian blue staining to identify microhemorrhages
using previously published protocols [32].
Aβ and IBA-1 immunostained slides were
imaged using an Aperio ScanScope XT digital
slidescanner at 40x magnification to create a high
resolution digital image. The Aperio positive pixel
count algorithm (version 9) was used to quantify
fields.
specific
staining
in
10-600x600µm2
Quantification of Prussian blue staining was by
counting microhemorrhages in each tissue section
using a 20X objective and counting within 10
fields/section. Prussian blue labeling within 2 cell
diameters of a blood vessel was considered a
microhemorrhage.

Statistical Analysis
Although the sample size was small, a repeated
t-test was used to compare the left and right
hemisphere Aβ loads in the two treatment groups and
in all 10 animals.

Results
The treatment parameters, including the number
of microbubble doses and sonication foci targeted, as
well as a summary of adverse events, are summarized
on a per-animal basis in Table 3.

CT and MRI findings
CT images from the 10 animals showing coronal
cross-sections of the skull bone are shown in Fig.2. It
can be seen that the bone thickness and geometry
varied substantially between animals. The dog skulls
had a mean thickness (± S.D.) of 3.2 ± 1.1 mm
(maximum
9.2
mm),
estimated
over
25
locations/skull, and a mean density (± S.D.) of 2172 ±
509 kg/m3 (maximum 3691 kg/m3). The brain cavities
of the 10 dog skulls were measured to be 42.5 ± 1.6
mm deep, 52.4 ± 1.5 mm wide and 71.2 ± 3.6 mm long.

http://www.thno.org
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Table 2. Neurological testing template
Mental Status:
Body Posture:
Gait:
Ataxia:
CRANIAL NERVES
Pupil (CN III):
Menace (CN II/VII):
PLR (CN II/III):
Strabismus (CN III/IV/VI):
Corneal Reflex (CN V/VI):
Jaw Tone (CN V):
Maxillary & Mandibular
(CN V):
Palpebral (CN V/VII)
Nystagmus (CN VIII):
POSTURAL REACTIONS
Proprioceptive positioning:
Hopping:
Wheelbarrow:
Extensor Postural Thrust:
Placing Reactions:

Categorize overall mental status:
BAR (bright, alert, responsive) / QAR (quiet, alert responsive) / Stuporous (only responsive to painful stimuli) / Comatose (non-responsive)
Describe any abnormal body posture:
Head Tilt (L/R) / Head Turn (L/R) / Circling (L/R)
Describe any abnormalities in gait, specifying involved limb(s):
Paresis (weakness of voluntary movement) / Paralysis (absence of voluntary movement) / Lameness (uneven gait caused by pain or stiffness)
Describe any irregular or inconsistent movements:
Proprioceptive (scuffing or dragging the paws on the ground, knuckling over, crossing over, or interference) / Vestibular (unable to walk in a
straight line) / Cerebellar (undershooting or overshooting of intended position with paw)
Record size, symmetry and shape of pupils
Make a threatening gesture at the eye to induce a blink
Shine a light into one eye and look for pupil constriction in both eyes
Eyes are not aligned due to lack of coordination between the extraocular muscles
Gently touch the cornea with a moist soft cotton swab to induce global retraction
Observe and palpate muscles of mastication for any swelling, atrophy, or asymmetry. Animal many not be able to close mouth if there is bilateral
weakness
Gently pinch the lips and look for retraction of the lips. Also, touch the medial nasal mucosa with a hemostat and look for retraction of the head
Gently touch the medial & lateral canthus of the eye to induce a blink response
Observe the eyes for nystagmus while moving the head slowly laterally in both directions, and up and down.
With the animal standing, turn over one paw and place the back of the paw on the floor. The animal should quickly correct the position of the paw.
Hold the animal so that all of its weight is supported by one limb and move the animal forward or laterally. The animal should make a quick,
smooth step in response
Lift the hind limbs off the ground and gently push the animal forward. The animal should make alternating steps with its forelimbs.
Hold the animal leaving just the hind limbs on the ground and gently push the animal backward. The animals should make coordinated steps
backwards.
Cover the animal's eyes and move the animal towards the edge of a table. The animal should place their paws on the table as soon as there is
contact

Fig.3. Baseline T1-weighted and T2-weighted axial MR images for the 5 subjects in the acute treatment group. The images for subjects 1, 2 and 3 have been resliced
from oblique image stacks. The scale bar is 2 cm.

To compare, the average thickness and density
of the supraorbital region of 8 ex vivo human skulls (4
skull caps and 4 full skulls) in our laboratory was
extracted from existing CT data. The human skulls
were found to be approximately twice as thick (6.4 ±
1.8 mm, maximum 20.3 mm) and were similar but not
quite as dense (1900 ± 373 kg/m3, maximum 2975
kg/m3) as the dog skulls. The brain cavities of the 4

full human skulls were 108.4 ± 4.2 mm deep, 137.2 ±
9.9 mm wide and 162.3 ± 5.2 mm long. Despite the
bone morphology, the permeability of the BBB was
successfully increased unilaterally using transcranial
ultrasound (Fig.4). A mean enhancement of 19 ± 11%
was observed across all treatments relative to the
untreated hemisphere. Heterogeneous patterns of
enhancement were observed in all animals.
http://www.thno.org
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Enhancement was not seen in the white matter tracts,
which is consistent with investigations of BBB
opening in primates [12] and can be attributed to the
fact that white matter is poorly vascularized resulting
in limited signal from the extravasated contrast agent.
The post-treatment images for animal #4 are missing
due to a data loss, but the degree of enhancement and
the heterogeneity of the enhancement were in keeping
with the other four animals in the single treatment
group. The mean intensity across the entire
hemisphere relative to the control hemisphere is
shown for each treatment and follow-up in Fig.5.
These are expressed as (1-mean_intensitytreated/
mean_intensityuntreated)*100%, and thus negative
values can occur when the mean intensity of the
treated side is lower than the control side. Also shown
are the mean intensity in an unsonicated region
(usually in the olfactory bulb or cerebellum) of the
treated hemisphere relative to the same region on the
treated side. This control region is included because in
some cases there were substantial differences in the
intensity of the MR images resulting from the
positioning of the surface coil. For example, the coil
placement during the follow-up imaging of animal #6

3579
resulted in an intensity gradient left to right across the
brain. Examining only the treated vs. untreated
intensities makes it appear that there is enhancement
in the treated region. Examining the unsonicated
control region, it can be seen that the higher intensity
in the left hemisphere is unrelated to the treatment
region. The heterogeneity of the BBB opening is
reflected by the large standard deviations in the
treated hemispheres.
At one week post treatment, the BBB was fully
intact in all animals and there were no indications of
damage to the brain tissue on the T2 and T2* weighted
images. In the first animal, thermal damage was seen
in the overlying muscle at follow-up and was
confirmed at necropsy. This was attributed to a
technical error that saw higher pressure exposures (>2
MPa), interleaved at several locations, applied in the
absence of injected microbubbles. Because there were
no bubbles in circulation, there was no associated
damage to the brain tissue observable by MRI or in
histology. Thermal damage was not seen in any of the
remaining animals, where the sonications were
correctly performed.

Fig.4. MR (axial) images from the 5 subjects in the acute treatment group acquired immediately post-treatment and at 7 days post-treatment. Contrast-enhanced
(CE) T1w images are shown on Day 0, and CE-T1w, T2w and T2* weighted images are shown for Day 7. The Day 0 image for subject #1 has been resliced from an
oblique plane. The Day 7 images for subject #3 were acquired using a different MRI scanner (Siemens Prisma). The scale bar is 2 cm.

http://www.thno.org
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Neurological testing and adverse events
All animals were alert and responsive following
the treatments. Gait and postural reactions were
consistent with baseline testing or the animals’ prior
health histories, and cranial nerve testing was normal
in all animals.
One minor adverse event was observed. 24 hr
following the second treatment, the first animal in the
chronic treatment group had bloody urine and was
vomiting. In consultation with the institutional
veterinarian this animal was given IV fluids and
started on oral antibiotics as a precaution. The
symptoms were resolved 24 hours following. As the
first animal in the repeat treatment group, the
treatment times for this animal were longer as the
treatment process had not been optimized. The
prolonged anesthesia time and the number of MRI
contrast agent injections were thought to have
contributed to the adverse reaction. For the remaining
treatments the MR imaging protocols on treatment
days were optimized to reduce the total treatment
time, and hence anesthetic time, and MRI contrast
agent injections were limited to two per treatment. No
adverse events were observed following these
modifications.

Tissue analysis
Table 3 details the results of the tissue analysis
on a per-animal basis. There were no statistically
significant reductions in Aβ load in the left
hemisphere as compared to the right hemisphere in
the single treatment group (t(4)=1.17 p=0.31) and
loads were significant correlated across hemispheres
(r=0.88 p=0.048). However, 3/5 dogs showed lower
left prefrontal cortex loads (Fig.6 A,B) relative to the
untreated right prefrontal cortex. In the multiple
treatment condition, a similar result was observed
with no statistically significant decreases in Aβ
(t(4)=0.12 p=0.98) but the two hemispheres were not
correlated (r=0.03 p=0.96). In this group, 3/5 dogs also
showed lower left prefrontal cortex Aβ compared to
right prefrontal cortex (Fig.6 C, D) but 2/5 animals
did not show any clear reduction of Aβ (Fig. 6 E, F). .
IBA-1 loads (Fig.7, Table 3) and the number of
microhemorrhages (Table 3) in the prefrontal cortex
were similar across hemispheres in both groups. In
the single treatment group, the mean number of
microhemorrhages in the treated side was 1.0 ± 1.4,
compared with 0.4 ± 0.5 on the untreated side. In the
multiple treatment condition, an average of 5.2 ± 1.8
microhemorrhages were detected in on the treated
size vs. 4.0 ± 2.0 on the contralateral size. Statistical
analysis was not performed due to the extremely low
counts.

Weight (kg)

# Treatments

Sonication
Scheme

Microbubble Doses
per Treatment Session*

# Foci Sonicated
per Treatment Session*

Neurological
Testing

Other Adverse
Events

9
10
11
10
10
11

12
12.5
11.7
10.1
12.1
12

1
1
1
1
1
4

A
B
B
B
B
B

6
12
9
12
13
11/9/9/9

49
50
36
48
52
44/34/34/36

normal
normal
normal
normal
normal
normal

7
8
9
10

F
F
F
M

11
10
10
11

13.8
10.6
12.8
12.1

4
4
4
4

B
B
B
B

10/9/8/9
8/7/8/7
8/8/12/8
8/12/8/7

40/35/31/35
30/28/32/27
31/32/48/31
31/46/32/28

normal
normal
normal
normal

none
none
none
none
none
vomiting/
bloody urine
none
none
none
none

Prussian Blue
(Treated/Control)

Age (yrs)

M
M
M
F
F
F

IBA-1
(Treated/Control)

Sex

1
2
3
4
5
6

6E10
(Treated/Control)

Animal #

Table 3. Summary of treatment parameters and outcomes. (A - Fixed pressure, 0.33 Hz PRF, 3 minutes, 9 interleaved foci per sonication
at 4 mm spacing; B - Actively controlled pressure, 1 Hz PRF, 2 minutes, up to 4 interleaved foci per sonication at 4.5 mm spacing; *
Variations in the number of injections and sonication spots per treatment for the repeated treatments is a result of variables such as animal
positioning (e.g. a different angle of the head requiring targeting at two different depths to ensure complete coverage of the brain) and
incomplete sonications (e.g. software crash halting the treatment mid-sonication and requiring a second sonication)

4.8/9.3
30.3/28.9
5.1/5.1
0.0/0.6
26.4/51.3
18.1/31.0

39.1/27.9
37.4/33.2
52.7/51.3
40.0/50.4
36.8/35.8
24.8/22.4

0/0
0/0
2/1
0/0
3/1
3/2

23.0/2.5
22.4/26.5
37.9/26.4
24.8/44.3

19.6/17.6
29.5/31.0
36.6/30.9
23.4/27.3

7/6
4/2
5/4
7/6
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canine model is therefore more representative of the
clinical scenario, where patients present with varying
levels of disease. Additionally, in this study the
animals had a range of underlying pathology and it is
possible that these pathologies may have interfered
with the treatment outcomes. However, this is also
more representative of what can be expected
clinically, where older patients may have
co-morbidities. Unfortunately this also means that a
much larger group size would be needed to observe
statistically significant changes in plaque load due to
treatment.

Fig.5. Mean enhancement of the treated hemisphere with respect to the
contralateral hemisphere for all animals, expressed as (1-mean_intensitytreated/
mean_intensityuntreated)*100%. The enhancement values are averaged over the
entire hemisphere. A control (unsonicated) region in the treated hemisphere is
also shown (compared to the same contralateral, untreated region) to eliminate
bias from spatial sensitivity of the MRI coil. The error bars indicate one standard
deviation.

Discussion
This study presents the first investigation of BBB
opening in a natural model of aging, and used a
large-volume treatment scheme at low, skull
penetrating frequency relevant to AD. These results
show that after a total of 920 sonications, transient
increase in the permeability of the BBB in a whole
hemisphere is well tolerated in the aged brain
following both single and repeated treatments
without any MRI or histological observation of brain
damage. One minor adverse event was observed,
from which the animal fully recovered and could be
attributable to effects from the anesthetic and/or MRI
contrast agent. Preliminary histological evidence
suggests that ultrasound treatments in a natural
disease model is safe and in 3/5 of our animals,
particularly in the repeated treatment condition, may
also impact plaque pathology as has been seen in
transgenic mouse models of AD [18, 19]. In this
natural model of aging the amount of plaque
pathology varied to a greater degree between animals
than the transgenic models, where similar levels of
burden are seen for animals of a given age. This

Fig.6. Representative examples of Aβ (6E10) immunostaining in the prefrontal
cortex of aged beagles in response to treatment. In a single treatment, the left
treated hemisphere shows less Aβ deposition (A) than the right untreated
hemisphere (B). Similarly, the left hemisphere of a dog given 4 treatments (C)
shows less Aβ than the right untreated hemisphere (D). In contrast, some dogs
with significant Aβ neuropathology do not show hemisphere treatment effect (E
– single treatment) and right untreated hemisphere (F). Panels A-F all have the
same magnification and the scale bar is 1.5 mm. The quantification of the Aβ
load is shown in panel (G) for the acute and chronic treatment groups.
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Fig.7. Representative examples of microglial (IBA-1) immunostaining in the
prefrontal cortex of aged beagles in response to treatment. In a single
treatment, the left treated hemisphere shows similar microglial “loads” (A) to
the right untreated hemisphere (B). Similarly, the left hemisphere of a dog given
4 treatments (C) shows similar microglial “loads” to the right untreated
hemisphere (D). Panels A-D all have the same magnification and the scale bar is
800 μm. Higher magnification (scale bar 150 μm) of sections from a dog given 4
treatments highlights the morphology of the microglial cells in the left prefrontal
cortex (E) as compared to the right prefrontal cortex (F). The quantification of
the microglial loads is shown in panel (G) for the acute and chronic treatment
groups.

The time course in this study is not ideal for
detecting changes in microglia activation, based on
work in transgenic mice showing that acutely (4 days)
IBA-1 staining is enhanced, but that this effect does
not persist to 15 days [17]. As the primary goal of this
study was to assess safety, a follow-up period to
monitor the animals was necessary, making it
impossible to examine the acute microglial response
given the small number of subjects available. Thus we
decided to measure chronic microglial activation as a
possible outcome from the ultrasound treatments, and
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found that in this natural model the results are in
agreement with work in transgenic rodents where a
sustained microglial response is not observed.
In this study we used a single element focused
transducer operating at a sufficiently low frequency to
allow transcranial treatment without having to correct
for phase distortions caused by the bone. In this
canine model, the parietal bone is relatively flat and
the animal can be positioned such that the sound has
almost normal incidence to the bone, allowing this
simple treatment platform to be used. However, the
length of the focal zone for this transducer is long
(~40mm) increasing the risk of non-negligible
reflections from the skull base. In addition the large
focal volume means that the exposure is controlled to
the location receiving the highest exposure and the
tissue heterogeneity in the focal volume is not
compensated for. This can be seen in the variability of
the contrast enhancement throughout the sonicated
hemisphere. Further the mechanical scanning
approach is relatively slow. In future studies, a large
aperture phased array transducer that can
electronically steer a tighter focal volume around the
field would allow for faster treatments with better
spatial control of the BBB opening [33].
Although comprehensive studies following
repeated, small volume BBB opening in healthy
non-human primates [12, 13] have been reported,
these canine studies provide important insight into
the safety of this treatment in aged dogs with
significant Aβ neuropathology. Further, the
disruption volume was much larger than has been
reported before and was well tolerated, as was the use
of multiple microbubble injections (up to 13) per
treatment. A previous study in a porcine model tested
multiple injections of bubbles at a reduced dose (0.002
ml/kg) to allow up to 10 sonications to be performed
while remaining within the recommended maximum
dose limit [34], however our study suggests that even
higher bubble doses may be safe for treatments
requiring serial sonications, as evidenced by our
successful use of up to 13 bubble injections at a dose of
0.2 ml/kg per injection. These results suggest that
ultrasound opening of the BBB in the aged brain may
be a safe treatment option but these preliminary data
also suggest the greatest benefit may be in
middle-aged dogs prior to Aβ accumulation. Further
studies are needed to determine if FUS has a positive
impact on naturally occurring Aβ pathology. A larger
beneficial effect might also be achieved in future
studies by combining the FUS opening of the BBB
with the delivery of a therapeutic, such as an Aβ
antibody [6], if FUS alone cannot produce a
therapeutically relevant effect.
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In addition to the small group size, another
limitation is that this study did not include a sham
treatment group as a control for the behavior testing
or histological analysis. However, the individuals
performing the behavior analysis were blinded to the
treatment hemisphere and the degree of BBB opening
(as determined by MRI enhancement) achieved
during treatment. Further, based on prior studies in
aged beagles that have not undergone ultrasound
treatments, it has been found that old dogs can have
widely varying Aβ loads [35, 36]. However, to our
knowledge, there are no studies directly comparing
Aβ deposition in the left and right hemispheres of
aging dogs, thus in future studies, it will be critical to
include sham treated animals.
Clinical Translation: A commercial device already
exists that would allow this technique to be
implemented in the clinic, and this device has
previously been tested in a healthy, large animal
model [34]. While the ultrasound frequency used in
this study is comparable to the commercial device,
some of the other study parameters may need to be
adjusted to be used in clinic. As discussed above, the
total dose of microbubbles/treatment was higher in
this study than the clinically recommended limit.
Although our study suggests that in the future a
higher total bubble dose, given over multiple
injections, could be safe, initially lower bubble doses
will most likely be used, similar to the scheme
described by [34]. During the repeated treatments we
limited the total number of MR contrast agent
injections to 2, following an adverse reaction.
Similarly, in the clinical setting it would be important
to limit the total dose of MR contrast. Finally, in our
study we used an active control scheme to ensure a
safe ultrasound exposure level. This controller is
currently not implemented in an automated fashion
on the commercial device, but a similar approach
could be manually implemented by increasing
exposures until the desired bubble behavior is
observed by the operator. This study demonstrates
the safety of this approach in a clinically-relevant
disease model with large treatment volumes and
paves the way for clinical testing in AD patients in the
very near future.
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